News

Filter

Current filters:

USAOphthalmicsHemangeol

1 to 9 of 95956 results

FDA lifts partial clinical hold for OncoMed’s vantictumab trials

29-08-2014

US biotech firm OncoMed Pharmaceuticals saw its shares leap 9.9% to $21.58 on Thursday on news that the…

BiotechnologyChief medical officerOncologyOncoMed PharmaceuticalsResearchRevised trial protocolsRevised trial protocolsUnited StatesUSAvantictumab

FTC puts conditions on acquisition of Insight Pharma by Prestige Brands

29-08-2014

US firm Prestige Brands Holdings, the maker of Dramamine (dimenhydrinate), has agreed to divest assets…

Insight PharmaceuticalsMergers & AcquisitionsPharmaceuticalPrestige BrandsRegulationUSA

Ipsen posts strong earnings growth for first-half 2014

29-08-2014

French drugmaker Ipsen has reported first half 2014 sales of 638.7 million euros ($845.1 million), up…

FinancialIpsenPharmaceutical

FDA approves Elelyso for pediatric use in Gaucher disease

29-08-2014

The US Food and Drug Administration has approved US pharma giant Pfizer’s Elelyso (taliglucerase alfa)…

ElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationUSA

Colorectal cancer market will remain steady at $7.7 billion by 2023; report

29-08-2014

The market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023…

EuropeJapanMarkets & MarketingOncologyPharmaceuticalUSA

Tau Therapeutics and Xdynia merge to form Cavion

29-08-2014

Privately-held US drugmakers Tau Therapeutics and Xdynia announced today that they have merged; the surviving…

CavionMergers & AcquisitionsNeurologicalOncologyPharmaceuticalTau TherapeuticsXdynia

India's Piramal will divert resources from early-stage research to advanced-stage molecules

India's Piramal will divert resources from early-stage research to advanced-stage molecules

29-08-2014

Indian pharma company Piramal Enterprises has announced its intention to stop early-stage research in…

IndiaMetabolic disordersPharmaceuticalPiramal EnterprisesPiramal HealthcareProductionResearchSwati PiramalUS Food and Drug Administration

Minomic to reformulate its MIL-38 prostate cancer screening target as a therapy with Catalent

Minomic to reformulate its MIL-38 prostate cancer screening target as a therapy with Catalent

29-08-2014

Australian biotech company Minomic International will join forces with Catalent Pharma to develop its…

AustraliaBiotechnologyCatalent PharmaMinomicOncologyProstate cancerProstate cancer screening technologyResearch

1 to 9 of 95956 results

Back to top